Finanziertes Projekt

No child with leukemia


Although less prevalent than in adults, children have cancer. Cure rates for childhood leukemias have improved a lot in recent years, but there is a group of pediatric leukemias with a very poor prognosis that continue to cause a lot of suffering for both the children who suffer from them and their families.

Finanziert dank:
  • Spender
  • Finanzierte Gesamtsumme
    • Bonpreu i Esclat Kunden 44.557€
  • Direkte Empfänger 250

    Diejenigen Personen, die auf natürliche Art direkt von den im Projekt ausgeführten Aktionen begünstigt wurden.

  • Indirekte Empfänger 500

    Diejenigen identifizierbaren Personen, die einen potentiellen Effekt von den im Projekt durchgeführten Aktionen erfahren.

Fundación Josep Carreras contra la leucemia


  • Materialien 18.770€
  • Personal 25.000€
  • Gesamt 43.770€


Acute B lymphoblastic leukemia (B-ALL) is the most common cancer in children under 18 years of age. Cure rates in pediatric leukemias for children over 2 years of age have greatly improved in recent years. However, childish leukemias are still considered a separate entity with a frightening diagnosis (5-year survival <20%). Childhood ALL-B has, beyond the emotional damage to families, dire consequences on the development of the child due to the multi-organ toxicity of current treatments.

The group of Dr. Pablo Menéndez from the Josep Carreras Foundation is an international leader in childhood B-ALL and has spent 20 years studying the origin of leukemia in the womb, the causes (etiology) and the mechanisms of the disease (pathogenesis). For 4 years, and motivated by the exclusion by the pharmaceutical industry of including children under one year of age in immunotherapies with T lymphocytes (CAR-T therapy), the group also investigates targeted and non-toxic immunotherapies for these children, in order to avoid the life-long consequences of survivors of current chemo therapy.


  • Generate a laboratory model that reproduces the disease in order to study how and why this type of leukemia develops.
  • Identify mechanisms that alter gene expression without mutating the DNA structure through the epigenetic study of these sick children.

Wer wird begünstigt?

Children under 2 years of age with a “denovo” diagnosis of acute leukemia, survivors of the disease at risk of relapses and future patients, given the higher prevalence in increasingly developed societies.


  • Identify the cell of origin and the leukemic stem cell responsible for relapse in these leukemias.
  • Improve CAR19 T cell immunotherapy for children <2 years of age.
  • Combine CAR19 T cell therapy with an anti-TIM3 antibody that is predicted to be highly effective based on preliminary preclinical studies.

Aktualisierungen und Links

Diese Seite verwendet Cookies. Wenn Sie weiter surfen, gehen wir davon aus, dass Sie die Verwendung akzeptieren. Mehr Information erhalten.